Is retardation of radiologic progression of ankylosing spondylitis possible?

Czech version

Authors: K. Pavelka
Authors‘ workplace: Revmatologický ústav Praha, ředitel prof. MUDr. Karel Pavelka, DrSc.
Published in: Vnitř Lék 2011; 57(11): 923-929
Category: Birthday

Overview

In the introduction is the author dealing with problems of early diagnosis of ankylosing spondylitis and he is explaining the advantages of new ASAS/EULAR criteria for diagnosis of axial spondylarthritis. Than he continues with discussion about new “Recommendations for treatment of ankylosing spondylitis”, stressing the modification of recommendations for anti-TNF therapy. Despite the fact, that high symptomatic efficacy of anti-TNF therapy was confirmed, there is no clear evidence that anti-TNF drugs delay radiologic progression. On the contrary, study with nonsteroidal antirheumatic drugs in duration 24 months was performed and have documented that patients treated continuously by celecoxib had smaller radiographic progression than patients treated with celecoxib on demand. Anti-TNF therapy delays radiographic progression in rheumatoid arthritis, but not NSAID, in ankylosing spondylitis it is opposite. The differences may be caused by different pathophysiology of rheumatoid arthritis and ankylosing spondylitis as it is explained in the next part of publication. Combination therapy of AS with anti-TNF and continuous celecoxib therapy could be very interesting.

Key words:
ankylosing spondylitis – therapy – coxibs

Sources

1. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York Criteria. Arthritis Rheum 1984; 27: 361–368.

2. Rudwaleit M, van der Heijde D, Landewé R et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68: 777–783.

3. Zochling J, van der Heide D, Burgos-Vargas R et al. ‚ASsessment in AS‘ international working group; European League Against Rheumatism. ASA/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442–452.

4. Braun J, van der Berg R, Baraliakos X et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70: 896–904.

5. Vosse D, Landewé R, van der Heijde D et al. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 2009; 68: 1839–1842.

6. Peters MJ, Visman I, Nielen MM et al. Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 2010; 69: 579–581.

7. Braun J, Baraliakos X, Listing J et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008; 67: 340–345.

8. van der Heijde D, Pangan AL, Schiff MH et al. ATLAS Study Group. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 2008; 67: 1218–1221.

9. Imman RD, Davis JC Jr, Heijde D et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis and Rheumatism 2008; 58: 3402–3412.

10. Braun J, van der Horst-Bruinsma IE, Huang F et al. Clinical efficacy and safety of etanercept versus sulfasalazine in ankylosing spondylitis patients: a randomized, double-blind study (ASCEND Trial). Arthritis and Rheumatism. Published Online First: 10 January 2011. doi.10.1002/art.30223.

11. Barkham N, Keen HI, Coates LC et al. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009; 60: 946–954.

12. Braun J, Baraliakos X, Listing J et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005; 52: 2447–2451.

13. Van der Heijde D, Klareskog L, Rodriguez-Valverde V et al. for the TEMPO study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006; 54: 1063–1074.

14. van der Hejde D, Landewé R, Einstein S et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008; 58: 1324–1331.

15. Sieper J, Rudwaleit M, Baraliakos X et al. The Assessment of Spondyloarthritis international society (ASAS) handbook: a guide to asses spondylarthritis. Ann Rheum Dis 2009; 68 (Suppl 2): ii1–ii44.

16. Creemers MC, Franssen MJ, van’t Hof MA et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005; 64: 127–129.

17. van der Heijde D, Landewé R, Baraliakos X et al. Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008; 10: 3063–3070.

18. Spoorenberg A, van der Heijde D, de Klerk E et al. A comparative study of the usefulness of the Bath Ankylosing Spondylitis functional index and the Dougados functional index in the assessment of ankylosing spondylitis. J Rheumatol 1999; 26: 961–965.

19. van der Heijde D, Landewé R, Einstein S et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008; 58: 1324–1331.

20. Schett G, Landewé R, van der Heijde D. Tumor necrosis factor blockers and structural remodeling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis 2007; 66: 709–711.

21. Diarra D, Stolina M, Polzer K et al. Dicklopf-1 is a master regulator of joint remodeling. Nat Med 2007; 13: 156–163.

22. Sieper J, Klopsch T, Richter M et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 2008; 67: 323–329.

23. Dougados M, Béhier JM, Jolchine I et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal anti-inflammatory drug. Arthritis Rheum 2001; 44: 180–185.

24. Zhang X, Schwarz EM, Young DA et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002; 109: 1405–1415.

25. Wanders A, van der Heijde D, Landewé R et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 6: 1756–1765.

26. Pavelka K. Doporučení České revmatologické společnosti pro léčbu ankylozující spondylitidy. Česk Revm 2011, v tisku.